These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 30304407)

  • 21. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
    Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL
    J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Systematic Review of Health Technology Assessments of Chimeric Antigen Receptor T-Cell Therapies in Young Compared With Older Patients.
    Gye A; Goodall S; De Abreu Lourenco R
    Value Health; 2022 Jan; 25(1):47-58. PubMed ID: 35031099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England.
    Petersohn S; Salles G; Wang M; Wu J; Wade SW; Simons CL; Bennison C; Siddiqi R; Peng W; Kloos I; Castaigne G; Hess G
    J Med Econ; 2022; 25(1):730-740. PubMed ID: 35611697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
    Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
    Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel.
    Ravich JW; Huang S; Zhou Y; Brown P; Pui CH; Inaba H; Cheng C; Gottschalk S; Triplett BM; Bonifant CL; Talleur AC
    Transplant Cell Ther; 2022 Feb; 28(2):73.e1-73.e9. PubMed ID: 34875402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective.
    Yang H; Hao Y; Chai X; Qi CZ; Wu EQ
    J Med Econ; 2020 Sep; 23(9):1016-1024. PubMed ID: 32397772
    [No Abstract]   [Full Text] [Related]  

  • 27. Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations.
    Halford Z; Anderson MK; Bennett LL; Moody J
    Ann Pharmacother; 2021 Apr; 55(4):466-479. PubMed ID: 32762363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tisagenlecleucel for relapsed/refractory acute lymphoblastic leukemia in the Irish healthcare setting: cost-effectiveness and value of information analysis.
    Carey N; Leahy J; Trela-Larsen L; McCullagh L; Barry M
    Int J Technol Assess Health Care; 2022 Jul; 38(1):e56. PubMed ID: 35815435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
    Schultz LM; Baggott C; Prabhu S; Pacenta HL; Phillips CL; Rossoff J; Stefanski HE; Talano JA; Moskop A; Margossian SP; Verneris MR; Myers GD; Karras NA; Brown PA; Qayed M; Hermiston M; Satwani P; Krupski C; Keating AK; Wilcox R; Rabik CA; Fabrizio VA; Rouce RH; Chinnabhandar V; Kunicki M; Barsan VV; Goksenin AY; Li Y; Mavroukakis S; Egeler E; Curran KJ; Mackall CL; Laetsch TW
    J Clin Oncol; 2022 Mar; 40(9):945-955. PubMed ID: 34882493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discrete Event Simulation to Incorporate Infusion Wait-Time When Assessing Cost-Effectiveness of a Chimeric-Antigen Receptor T Cell Therapy.
    Gye A; Lourenco RA; Goodall S
    Value Health; 2024 Apr; 27(4):415-424. PubMed ID: 38301961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective.
    Wang XJ; Wang YH; Ong MJC; Gkitzia C; Soh SY; Hwang WYK
    Clinicoecon Outcomes Res; 2022; 14():333-355. PubMed ID: 35535300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results.
    Oluwole OO; Ray MD; Davies N; Bradford R; Jones C; Patel AR; Locke FL
    J Med Econ; 2024; 27(1):230-239. PubMed ID: 38240256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study.
    Laetsch T; Zhang J; Yang H; Xie Y; Zhang D; Garrison L
    Appl Health Econ Health Policy; 2024 Sep; 22(5):749-765. PubMed ID: 38683438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.
    Laetsch TW; Myers GD; Baruchel A; Dietz AC; Pulsipher MA; Bittencourt H; Buechner J; De Moerloose B; Davis KL; Nemecek E; Driscoll T; Mechinaud F; Boissel N; Rives S; Bader P; Peters C; Sabnis HS; Grupp SA; Yanik GA; Hiramatsu H; Stefanski HE; Rasouliyan L; Yi L; Shah S; Zhang J; Harris AC
    Lancet Oncol; 2019 Dec; 20(12):1710-1718. PubMed ID: 31606419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States.
    Simons CL; Malone D; Wang M; Maglinte GA; Inocencio T; Wade SW; Bennison C; Shah B
    J Med Econ; 2021; 24(1):421-431. PubMed ID: 33634729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain.
    Ribera Santasusana JM; de Andrés Saldaña A; García-Muñoz N; Gostkorzewicz J; Martínez Llinàs D; Díaz de Heredia C
    Clinicoecon Outcomes Res; 2020; 12():253-264. PubMed ID: 32523362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
    Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
    J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study.
    Ghorashian S; Jacoby E; De Moerloose B; Rives S; Bonney D; Shenton G; Bader P; Bodmer N; Quintana AM; Herrero B; Algeri M; Locatelli F; Vettenranta K; Gonzalez B; Attarbaschi A; Harris S; Bourquin JP; Baruchel A
    Lancet Haematol; 2022 Oct; 9(10):e766-e775. PubMed ID: 36084658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.
    Roth JA; Sullivan SD; Lin VW; Bansal A; Purdum AG; Navale L; Cheng P; Ramsey SD
    J Med Econ; 2018 Dec; 21(12):1238-1245. PubMed ID: 30260711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.